Carotid artery stenting with distal protection using the Carotid Wallstent and FilterWire neuroprotection: Single-center experience of 380 cases with midterm outcomes

Peter H. Lin, Wei Zhou, Marlon A Guerrero, Sally A. McCoy, Deborah Felkai, Panos Kougias, Hosam F. El Sayed

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Emerging data have supported the clinical efficacy of carotid artery stenting (CAS) in stroke prevention in high-risk surgical patients. This study was performed to evaluate the midterm clinical outcome of CAS using the Carotid Wallstent and FilterWire distal protection (both Boston Scientific, Natick, MA) at an academic institution. Risk factors for in-stent restenosis (ISR) were also analyzed. Clinical variables and treatment outcome of high-risk patients who underwent Carotid Wallstent placement with FilterWire EX/EZ neuroprotection were analyzed during a recent 54-month period. Three hundred eighty CAS procedures were performed in 354 patients. Technical success was achieved in 372 cases (98%), and symptomatic lesions existed in 85 (24%) patients. No patient experienced periprocedural mortality or neuroprotective device-related complication. The 30-day stroke and death rate was 2.7%, and the overall complication rate was 6.9%. The overall major or fatal stroke rates in symptomatic and asymptomatic patients were 4.6% and 1.3%, respectively (not significant). The overall stroke and death rates between the symptomatic and asymptomatic groups were 5.8% and 2.4%, respectively (not significant). The median follow-up period was 29 months (range 1-53 months). With Kaplan-Meier analysis, the rates of freedom from 60% or greater ISR after CAS procedures at 12, 24, 36, and 48 months were 97%, 94%, 92%, and 90%, respectively. The rates of freedom from all fatal and nonfatal strokes at 12, 24, 36, and 48 months were 97%, 91%, 89%, and 85%, respectively. Multivariable analysis of significant univariate predictors identified that postendarterectomy stenosis (odds ratio [OR] 3.98, p = .02) and multiple stent placement (OR 3.68, p = .03) were independent predictors of ISR. Our study yielded favorable short-term and midterm clinical results using Carotid Wallstent with FilterWire neuroprotection. Late follow-up results showed low rates of fatal and nonfatal stroke and favorable ISR rates compared with other carotid stent trials. Postendarterectomy and multiple stent placement were associated with subsequent ISR.

Original languageEnglish (US)
Pages (from-to)237-244
Number of pages8
JournalVascular
Volume14
Issue number5
DOIs
StatePublished - Sep 2006
Externally publishedYes

Fingerprint

Carotid Arteries
Stents
Stroke
Mortality
Odds Ratio
Neuroprotection
Kaplan-Meier Estimate
Pathologic Constriction
Equipment and Supplies

Keywords

  • Carotid artery stenting
  • Distal protection device
  • High-risk patients
  • Restenosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging
  • Surgery

Cite this

Carotid artery stenting with distal protection using the Carotid Wallstent and FilterWire neuroprotection : Single-center experience of 380 cases with midterm outcomes. / Lin, Peter H.; Zhou, Wei; Guerrero, Marlon A; McCoy, Sally A.; Felkai, Deborah; Kougias, Panos; El Sayed, Hosam F.

In: Vascular, Vol. 14, No. 5, 09.2006, p. 237-244.

Research output: Contribution to journalArticle

Lin, Peter H. ; Zhou, Wei ; Guerrero, Marlon A ; McCoy, Sally A. ; Felkai, Deborah ; Kougias, Panos ; El Sayed, Hosam F. / Carotid artery stenting with distal protection using the Carotid Wallstent and FilterWire neuroprotection : Single-center experience of 380 cases with midterm outcomes. In: Vascular. 2006 ; Vol. 14, No. 5. pp. 237-244.
@article{588390654aa044eb81e4547dde08e9ca,
title = "Carotid artery stenting with distal protection using the Carotid Wallstent and FilterWire neuroprotection: Single-center experience of 380 cases with midterm outcomes",
abstract = "Emerging data have supported the clinical efficacy of carotid artery stenting (CAS) in stroke prevention in high-risk surgical patients. This study was performed to evaluate the midterm clinical outcome of CAS using the Carotid Wallstent and FilterWire distal protection (both Boston Scientific, Natick, MA) at an academic institution. Risk factors for in-stent restenosis (ISR) were also analyzed. Clinical variables and treatment outcome of high-risk patients who underwent Carotid Wallstent placement with FilterWire EX/EZ neuroprotection were analyzed during a recent 54-month period. Three hundred eighty CAS procedures were performed in 354 patients. Technical success was achieved in 372 cases (98{\%}), and symptomatic lesions existed in 85 (24{\%}) patients. No patient experienced periprocedural mortality or neuroprotective device-related complication. The 30-day stroke and death rate was 2.7{\%}, and the overall complication rate was 6.9{\%}. The overall major or fatal stroke rates in symptomatic and asymptomatic patients were 4.6{\%} and 1.3{\%}, respectively (not significant). The overall stroke and death rates between the symptomatic and asymptomatic groups were 5.8{\%} and 2.4{\%}, respectively (not significant). The median follow-up period was 29 months (range 1-53 months). With Kaplan-Meier analysis, the rates of freedom from 60{\%} or greater ISR after CAS procedures at 12, 24, 36, and 48 months were 97{\%}, 94{\%}, 92{\%}, and 90{\%}, respectively. The rates of freedom from all fatal and nonfatal strokes at 12, 24, 36, and 48 months were 97{\%}, 91{\%}, 89{\%}, and 85{\%}, respectively. Multivariable analysis of significant univariate predictors identified that postendarterectomy stenosis (odds ratio [OR] 3.98, p = .02) and multiple stent placement (OR 3.68, p = .03) were independent predictors of ISR. Our study yielded favorable short-term and midterm clinical results using Carotid Wallstent with FilterWire neuroprotection. Late follow-up results showed low rates of fatal and nonfatal stroke and favorable ISR rates compared with other carotid stent trials. Postendarterectomy and multiple stent placement were associated with subsequent ISR.",
keywords = "Carotid artery stenting, Distal protection device, High-risk patients, Restenosis",
author = "Lin, {Peter H.} and Wei Zhou and Guerrero, {Marlon A} and McCoy, {Sally A.} and Deborah Felkai and Panos Kougias and {El Sayed}, {Hosam F.}",
year = "2006",
month = "9",
doi = "10.2310/6670.2006.00054",
language = "English (US)",
volume = "14",
pages = "237--244",
journal = "Vascular",
issn = "1708-5381",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Carotid artery stenting with distal protection using the Carotid Wallstent and FilterWire neuroprotection

T2 - Single-center experience of 380 cases with midterm outcomes

AU - Lin, Peter H.

AU - Zhou, Wei

AU - Guerrero, Marlon A

AU - McCoy, Sally A.

AU - Felkai, Deborah

AU - Kougias, Panos

AU - El Sayed, Hosam F.

PY - 2006/9

Y1 - 2006/9

N2 - Emerging data have supported the clinical efficacy of carotid artery stenting (CAS) in stroke prevention in high-risk surgical patients. This study was performed to evaluate the midterm clinical outcome of CAS using the Carotid Wallstent and FilterWire distal protection (both Boston Scientific, Natick, MA) at an academic institution. Risk factors for in-stent restenosis (ISR) were also analyzed. Clinical variables and treatment outcome of high-risk patients who underwent Carotid Wallstent placement with FilterWire EX/EZ neuroprotection were analyzed during a recent 54-month period. Three hundred eighty CAS procedures were performed in 354 patients. Technical success was achieved in 372 cases (98%), and symptomatic lesions existed in 85 (24%) patients. No patient experienced periprocedural mortality or neuroprotective device-related complication. The 30-day stroke and death rate was 2.7%, and the overall complication rate was 6.9%. The overall major or fatal stroke rates in symptomatic and asymptomatic patients were 4.6% and 1.3%, respectively (not significant). The overall stroke and death rates between the symptomatic and asymptomatic groups were 5.8% and 2.4%, respectively (not significant). The median follow-up period was 29 months (range 1-53 months). With Kaplan-Meier analysis, the rates of freedom from 60% or greater ISR after CAS procedures at 12, 24, 36, and 48 months were 97%, 94%, 92%, and 90%, respectively. The rates of freedom from all fatal and nonfatal strokes at 12, 24, 36, and 48 months were 97%, 91%, 89%, and 85%, respectively. Multivariable analysis of significant univariate predictors identified that postendarterectomy stenosis (odds ratio [OR] 3.98, p = .02) and multiple stent placement (OR 3.68, p = .03) were independent predictors of ISR. Our study yielded favorable short-term and midterm clinical results using Carotid Wallstent with FilterWire neuroprotection. Late follow-up results showed low rates of fatal and nonfatal stroke and favorable ISR rates compared with other carotid stent trials. Postendarterectomy and multiple stent placement were associated with subsequent ISR.

AB - Emerging data have supported the clinical efficacy of carotid artery stenting (CAS) in stroke prevention in high-risk surgical patients. This study was performed to evaluate the midterm clinical outcome of CAS using the Carotid Wallstent and FilterWire distal protection (both Boston Scientific, Natick, MA) at an academic institution. Risk factors for in-stent restenosis (ISR) were also analyzed. Clinical variables and treatment outcome of high-risk patients who underwent Carotid Wallstent placement with FilterWire EX/EZ neuroprotection were analyzed during a recent 54-month period. Three hundred eighty CAS procedures were performed in 354 patients. Technical success was achieved in 372 cases (98%), and symptomatic lesions existed in 85 (24%) patients. No patient experienced periprocedural mortality or neuroprotective device-related complication. The 30-day stroke and death rate was 2.7%, and the overall complication rate was 6.9%. The overall major or fatal stroke rates in symptomatic and asymptomatic patients were 4.6% and 1.3%, respectively (not significant). The overall stroke and death rates between the symptomatic and asymptomatic groups were 5.8% and 2.4%, respectively (not significant). The median follow-up period was 29 months (range 1-53 months). With Kaplan-Meier analysis, the rates of freedom from 60% or greater ISR after CAS procedures at 12, 24, 36, and 48 months were 97%, 94%, 92%, and 90%, respectively. The rates of freedom from all fatal and nonfatal strokes at 12, 24, 36, and 48 months were 97%, 91%, 89%, and 85%, respectively. Multivariable analysis of significant univariate predictors identified that postendarterectomy stenosis (odds ratio [OR] 3.98, p = .02) and multiple stent placement (OR 3.68, p = .03) were independent predictors of ISR. Our study yielded favorable short-term and midterm clinical results using Carotid Wallstent with FilterWire neuroprotection. Late follow-up results showed low rates of fatal and nonfatal stroke and favorable ISR rates compared with other carotid stent trials. Postendarterectomy and multiple stent placement were associated with subsequent ISR.

KW - Carotid artery stenting

KW - Distal protection device

KW - High-risk patients

KW - Restenosis

UR - http://www.scopus.com/inward/record.url?scp=33845208158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845208158&partnerID=8YFLogxK

U2 - 10.2310/6670.2006.00054

DO - 10.2310/6670.2006.00054

M3 - Article

C2 - 17038293

AN - SCOPUS:33845208158

VL - 14

SP - 237

EP - 244

JO - Vascular

JF - Vascular

SN - 1708-5381

IS - 5

ER -